Shutterstock.com has buy call on with a target price of Rs 1700. The current market price of Gland Pharma is Rs 1349.45.
Gland Pharma, incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 22233.18 Crore) operating in Pharmaceuticals sector.
Gland Pharma key Products/Revenue Segments include Pharmaceuticals, Sale of services and Export Incentives for the year ending 31-Mar-2022.
Financials
For the quarter ended 30-09-2022, the company has reported a Consolidated Total Income of Rs 1110.03 Crore, up 19.19 % from last quarter Total Income of Rs 931.29 Crore and down -1.91 % from last year same quarter Total Income of Rs 1131.67 Crore. Company has reported net profit after tax of Rs 241.24 Crore in latest quarter.
The company’s top management includes Mr.Yiu Kwan Stanley Lau, Mr.Essaji Goolam Vahanvati, Mr.Satyanarayana Murthy Chavali, Dr.Jia Ai (Allen) Zhang, Mr.Udo Johannes Vetter, Ms.Xiaohui Guan, Mr.Yao Fang, Mr.Yifang Wu, Mr.Qiyu Chen, Mr.Srinivas Sadu, Ms.Naina Lal Kidwai. Company has S R & Associates LLP as its auditors. As on 31-12-2022, the company has a total of 16 Crore shares outstanding.
Investment Rationale
Considering near-term business headwinds, the brokerage expects a 22% earnings decline YoY in FY23. However, with the resolution of issues, a better business outlook for biologics/China and the addition of Cenexi’s business, Motilal Oswal expects a 17% earnings CAGR over FY23-25. The 58% fall in the stock price in the past one year already factors in the deterioration in the business outlook.
Promoter/FII Holdings
Promoters held 57.86 per cent stake in the company as of 31-Dec-2022, while FIIs owned 4.67 per cent, DIIs 23.13 per cent.
Gland Pharma, incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 22233.18 Crore) operating in Pharmaceuticals sector.
Gland Pharma key Products/Revenue Segments include Pharmaceuticals, Sale of services and Export Incentives for the year ending 31-Mar-2022.
Financials
For the quarter ended 30-09-2022, the company has reported a Consolidated Total Income of Rs 1110.03 Crore, up 19.19 % from last quarter Total Income of Rs 931.29 Crore and down -1.91 % from last year same quarter Total Income of Rs 1131.67 Crore. Company has reported net profit after tax of Rs 241.24 Crore in latest quarter.
The company’s top management includes Mr.Yiu Kwan Stanley Lau, Mr.Essaji Goolam Vahanvati, Mr.Satyanarayana Murthy Chavali, Dr.Jia Ai (Allen) Zhang, Mr.Udo Johannes Vetter, Ms.Xiaohui Guan, Mr.Yao Fang, Mr.Yifang Wu, Mr.Qiyu Chen, Mr.Srinivas Sadu, Ms.Naina Lal Kidwai. Company has S R & Associates LLP as its auditors. As on 31-12-2022, the company has a total of 16 Crore shares outstanding.
Investment Rationale
Considering near-term business headwinds, the brokerage expects a 22% earnings decline YoY in FY23. However, with the resolution of issues, a better business outlook for biologics/China and the addition of Cenexi’s business, Motilal Oswal expects a 17% earnings CAGR over FY23-25. The 58% fall in the stock price in the past one year already factors in the deterioration in the business outlook.
Promoter/FII Holdings
Promoters held 57.86 per cent stake in the company as of 31-Dec-2022, while FIIs owned 4.67 per cent, DIIs 23.13 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
Read More News on
(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.